Heterozygous Deficiency of Hypoxia-inducible Factor-2alpha Protects Mice Against Pulmonary Hypertension and Right Ventricular Dysfunction During Prolonged Hypoxia

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2003 May 17

PMID 12750401

Citations 165

Authors

Koen Brusselmans

Veerle Compernolle

Marc Tjwa

Michael S Wiesener

Patrick H Maxwell

Desire Collen

Peter Carmeliet

Affiliations

Soon will be listed here.

Abstract

Chronic hypoxia induces pulmonary vascular remodeling, leading to pulmonary hypertension, right ventricular hypertrophy, and heart failure. Heterozygous deficiency of hypoxia-inducible factor-1alpha (HIF-1alpha), which mediates the cellular response to hypoxia by increasing expression of genes involved in erythropoiesis and angiogenesis, has been previously shown to delay hypoxia-induced pulmonary hypertension. HIF-2alpha is a homologue of HIF-1alpha and is abundantly expressed in the lung, but its role in pulmonary hypertension remains unknown. Therefore, we analyzed the pulmonary response of WT and viable heterozygous HIF-2alpha-deficient (Hif2alpha(+/-)) mice after exposure to 10% O(2) for 4 weeks. In contrast to WT mice, Hif2alpha(+/-) mice were fully protected against pulmonary hypertension and right ventricular hypertrophy, unveiling a critical role of HIF-2alpha in hypoxia-induced pulmonary vascular remodeling. Pulmonary expression levels of endothelin-1 and plasma catecholamine levels were increased threefold and 12-fold respectively in WT but not in Hif2alpha(+/-) mice after hypoxia, suggesting that HIF-2alpha-mediated upregulation of these vasoconstrictors contributes to the development of hypoxic pulmonary vascular remodeling.

Citing Articles

Unraveling the role of HIF and epigenetic regulation in pulmonary arterial hypertension: implications for clinical research and its therapeutic approach.

Mitra A, Yi D, Dai Z, De Jesus Perez V Front Med (Lausanne). 2024; 11:1460376.

PMID: 39450110 PMC: 11499164. DOI: 10.3389/fmed.2024.1460376.

Endothelial PHD2 deficiency induces apoptosis resistance and inflammation via AKT activation and AIP1 loss independent of HIF2α.

Wang S, Awad K, Chen L, Siddique M, Ferreyra G, Wang C Am J Physiol Lung Cell Mol Physiol. 2024; 327(4):L503-L519.

PMID: 39159362 PMC: 11482463. DOI: 10.1152/ajplung.00077.2024.

Aspects on Oxygenation in Preterm Infants before, Immediately after Birth, and Beyond.

Sotiropoulos J, Saugstad O, Oei J Neonatology. 2024; 121(5):562-569.

PMID: 39089224 PMC: 11446306. DOI: 10.1159/000540481.

HIF3A gene disruption causes abnormal alveoli structure and early neonatal death.

Kawahata T, Tanaka K, Oyama K, Ueda J, Okamoto K, Makino Y PLoS One. 2024; 19(5):e0300751.

PMID: 38717999 PMC: 11078382. DOI: 10.1371/journal.pone.0300751.

Endothelial HIFα/PDGF-B to smooth muscle Beclin1 signaling sustains pathological muscularization in pulmonary hypertension.

Saddouk F, Kuzemczak A, Saito J, Greif D JCI Insight. 2024; 9(10).

PMID: 38652543 PMC: 11141934. DOI: 10.1172/jci.insight.162449.

References

Durmowicz A, Stenmark K . Mechanisms of structural remodeling in chronic pulmonary hypertension. Pediatr Rev. 1999; 20(11):e91-e102. View

Champion H, Bivalacqua T, DSouza F, Ortiz L, Jeter J, Toyoda K . Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo. Effect on agonist-induced and flow-mediated vascular responses. Circ Res. 1999; 84(12):1422-32. DOI: 10.1161/01.res.84.12.1422. View

Suzuki J, Baba S, Ohno I, Endoh M, Nawata J, Miura S . Immunohistochemical analysis of platelet-derived growth factor-B expression in myocardial tissues in hypertrophic cardiomyopathy. Cardiovasc Pathol. 2000; 8(4):223-31. DOI: 10.1016/s1054-8807(99)00015-0. View

Eddahibi S, Hanoun N, Lanfumey L, Lesch K, Raffestin B, Hamon M . Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest. 2000; 105(11):1555-62. PMC: 300850. DOI: 10.1172/JCI8678. View

Barnes P . Chronic obstructive pulmonary disease. N Engl J Med. 2000; 343(4):269-80. DOI: 10.1056/NEJM200007273430407. View

Peng J, Zhang L, Drysdale L, Fong G . The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling. Proc Natl Acad Sci U S A. 2000; 97(15):8386-91. PMC: 26957. DOI: 10.1073/pnas.140087397. View

Chen Y, Oparil S . Endothelin and pulmonary hypertension. J Cardiovasc Pharmacol. 2000; 35(4 Suppl 2):S49-53. DOI: 10.1097/00005344-200000002-00012. View

Voelkel N, Tuder R . Hypoxia-induced pulmonary vascular remodeling: a model for what human disease?. J Clin Invest. 2000; 106(6):733-8. PMC: 381402. DOI: 10.1172/JCI11144. View

Kung A, Wang S, Klco J, Kaelin W, Livingston D . Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med. 2000; 6(12):1335-40. DOI: 10.1038/82146. View

10.

Budts W, Pokreisz P, Nong Z, van Pelt N, Gillijns H, Gerard R . Aerosol gene transfer with inducible nitric oxide synthase reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats. Circulation. 2000; 102(23):2880-5. DOI: 10.1161/01.cir.102.23.2880. View

11.

Jones R, Thompson J, Morice A . The NADPH oxidase inhibitors iodonium diphenyl and cadmium sulphate inhibit hypoxic pulmonary vasoconstriction in isolated rat pulmonary arteries. Physiol Res. 2001; 49(5):587-96. View

12.

Bratel T, Wennlund A, Carlstrom K . Impact of hypoxaemia on neuroendocrine function and catecholamine secretion in chronic obstructive pulmonary disease (COPD). Effects of long-term oxygen treatment. Respir Med. 2001; 94(12):1221-8. DOI: 10.1053/rmed.2000.0953. View

13.

Barbera J, Peinado V, Santos S . Pulmonary hypertension in COPD: old and new concepts. Monaldi Arch Chest Dis. 2001; 55(6):445-9. View

14.

Gross N . Extrapulmonary effects of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2001; 7(2):84-92. DOI: 10.1097/00063198-200103000-00006. View

15.

Le Cras T, McMurtry I . Nitric oxide production in the hypoxic lung. Am J Physiol Lung Cell Mol Physiol. 2001; 280(4):L575-82. DOI: 10.1152/ajplung.2001.280.4.L575. View

16.

Levi M, Moons L, Bouche A, Shapiro S, Collen D, Carmeliet P . Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice. Circulation. 2001; 103(15):2014-20. DOI: 10.1161/01.cir.103.15.2014. View

17.

Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, de Mol M . Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001; 7(5):575-83. DOI: 10.1038/87904. View

18.

Shimoda L, Manalo D, Sham J, Semenza G, Sylvester J . Partial HIF-1alpha deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia. Am J Physiol Lung Cell Mol Physiol. 2001; 281(1):L202-8. DOI: 10.1152/ajplung.2001.281.1.L202. View

19.

Hoshikawa Y, Voelkel N, Gesell T, Moore M, Morris K, Alger L . Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med. 2001; 164(2):314-8. DOI: 10.1164/ajrccm.164.2.2010150. View

20.

Wort S, Woods M, Warner T, Evans T, Mitchell J . Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling. Am J Respir Cell Mol Biol. 2001; 25(1):104-10. DOI: 10.1165/ajrcmb.25.1.4331. View